Group items tagged

he British Generic Manufacturers Association (BGMA) has voted Pete Kelly, managing director of Accord UK, to become its new chair. He replaces Peter Ballard, who has completed his second tenure as the association's chair and will now serve a further year as vice-chair. Pete leads the UK operations of Accord, one of the largest generic and biosimilar manufacturers in Europe. In the UK, the company currently supplies a fifth of all generic medicines. Mark Samuels, chief executive of BGMA, said: "We are very fortunate to have someone of Pete's experience and leadership qualities to take on the mantle of chair of the association. The industry faces a challenging period on many fronts, and Pete's input will be invaluable. "I would also like to record my enormous gratitude to Peter Ballard, our out-going Chair who has been an incredible servant to the association over many, many years. He will continue for another year as vice-chair, and we are pleased to have his continuing advice."

Family Eye Care has hundreds of eyewear glasses styles in the Missouri area. We are providing different brand of eyewear glasses in St. Louis, Overland, Maryland Heights, Bridgeton, St. Charles, St. Peters, Wentzville and O'Fallon area.

The British Generic Manufacturers Association (BGMA) has elected Diane DiGangi Trench to be its new vice-chair. DiGangi Trench takes up the position replacing Xiromed's Peter Ballard and in 12-months' time will assume the association's chair role from Accord's Peter Kelly. With over 25 years of pharmaceutical industry experience, DiGangi Trench has held a number of senior commercial roles including stints with Takeda and Astra Zeneca. She joined Sandoz in 2018 in the US, where she served as Vice-President, Market Access and Patient Services. In 2021, she became the head of Sandoz' UK business and in her two years in role, she has led the organisation through a post-COVID recovery and growth phase to prepare for the proposed spin out of the company from its parent, Novartis, expected later this year. She said: "It's a great honor to take on the role of Vice Chair of the BGMA. The success of the generics and biosimilar industry is essential to the functioning of the NHS. Generic medicines fill four out of five UK prescriptions and biosimilars enable the NHS to expand access to more patients. I am passionate about increasing the sustainability of our industry so we can continue to play our vital part in the health of the nation." Mark Samuels, BGMA chief executive, said: "We are extremely fortunate to be able to call upon the expertise of Diane who has already added significant value through her role on the BGMA board and leadership of a key strategic committee.

The Association of Independent Multiple Pharmacies (AIMp) has appointed David Vanns as its non-executive Chairman following the retirement of its long serving Chair Peter Cattee. Vanns will take up the role from April 2023. Cattee, one of the co-founders of AIMp took up the role as its Chairman in 2000. He is also a non-CCA representative on the PSNC. Despite retiring as chairman Cattee will remain on the AIMp board. Commenting on his retirement Cattee said: "It's been my great good fortune to work with almost all of the owners of pharmacy groups throughout England, Scotland and Wales over the years and many other talented people throughout the sector. It's been during a period of increasing consolidation, something which our own business has reflected, and the original founders and Board members Yakub Patel, Kirit Patel, Steve Williams and David Vanns have all been instrumental in shaping pharmacy negotiations to better reflect the views of our natural constituency - pharmacy group owners. A spokesperson for AIMp said: "We thank Peter for his services and dedication to AIMp throughout the years. Our organisation has grown to be a diverse and dynamic organisation representing and supporting pharmacy groups of all sizes, small and large. Our main identity and what unites us in AIMp, irrespective of the size of the pharmacy group, is being Independents, and we are very proud of our identity. We look forward to continuing our work in representing and supporting our members in the best way possible."

Generic and over-the-counter drugs company Stada has asked the German government to seek assurances from Ukraine that the company can continue operations there even though it also does business in Russia. In a March 21 letter to German Economy Minister Robert Habeck, Stada CEO Peter Goldschmidt said there was a risk Kyiv might withdraw the company's market authorisation. Stada "still has no longer-term certainty that we will be able to sell our products in Ukraine in the future," the letter said, with the subject line: "Please prevent the exclusion of international pharmaceutical companies from the Ukrainian market." The Economy Ministry did not have an immediate comment on the letter. Habeck promised investment guarantees for German companies during a trip to Ukraine on Tuesday (April 4) as part of his goal to speed up reconstruction in the war-torn country. Goldschmidt said restricting Stada's operations would be bad for Ukraine.

Community Pharmacy England (CPE) highlighted the untapped potential of community pharmacies in the prevention and management of long-term conditions to Conservative MPs during an event last week. The roundtable discussion was attended by a select group of influential and supportive MPs alongside community pharmacy owners, the Chief Executive of Community Pharmacy England, the Director of NHS Services, and patient representative group Healthwatch. MPs in attendance included Steve Double, MP for St Austell and Newquay, who chaired the discussion; Will Quince MP, former Minister for Pharmacy, Derek Thomas MP, Sir Peter Bottomley and Peter Aldous MP. They talked about the current pressures and funding crisis in community pharmacy, exploring solutions on how this could be eased and the huge benefits that can be unlocked.

Be sure they specialize in eyeglass repair of your specific type of glasses. With the various brands & types of glasses, be sure yours are in gook, capable hands. You can trust the professionals at Overland Optical. We are a leading medical eye care provider, offering a high level of experience & expertise to families in the St. Louis, Missouri.

Your vision is likely to be one of your most valuable senses, you want to consider your visit to the eye doctor as important an opportunity to review your health status as your regular checkup with your physician.

A Nottingham-based pharmacist has been struck off the General Pharmaceutical Council (GPhC) register for bringing "the profession into to disrepute" by stealing hundreds of thousands of pounds in a bid to settle his gambling debt. Peter Sameh Saad (33) spun a web of lies and duped a friend out of more than half a million pounds to fund his addiction and pretended he had "serious if not terminal" testicular cancer. "It is difficult to imagine a more heinous fraud than one predicated on feigning a cancer diagnosis", a GPC panel ruled. Saad committed three frauds on a total of £536,689.95 between September 2018 and May 2019. First, he tricked a friend, whom he knew through his local church, into sending him around £288,200 by claiming that his newly-purchased pharmacy in US was "seized" by the authorities over visa issues and that he "had some difficulty making the mortgage payments". Later Saad conned the same friend, named only as 'Person A' in court documents, into sending him a total of £127,150 by lying about a non-existent cancer diagnosis and private treatment. Finally, he extracted a further £121,339.95 from an investments and credit group (named Company A) of which his friend was chief executive after inviting him to set up a 'pharmaceutical warehouse', a plan that "impressed Person A and he agreed to invest in the business."

Instability in the supply chain network is frequently undermining the profit margins in community pharmacies, former Pharmacy Minister and Chair of the Health and Social Care Committee Steve Brine has said. Brine emphasised that community pharmacies often lack information about the prices wholesalers charge for essential generic medications. "They lack visibility into scarcity, and the pricing of these products is often significantly higher compared to other European countries," the former minister remarked during a parliamentary debate focused on the future of community pharmacies on September 14. From financial pressures to workforce crisis and pharmacy closures, the debate delved into critical challenges faced by pharmacies, aiming to propose tangible solutions for a sustainable future in the sector. Chaired by Sir Mark Hendrik, the debate was initiated by Conservative MP Peter Aldous and featured contributions from a host of participants including Labour MPs Taiwo Owatemi and George Howarth among others.

The Royal Pharmaceutical Society has designated four pharmacists in Scotland as its fellows in recognition of their services to the profession. Pharmacists Paul Forsyth, Alasdair MacIntryre and Peter Mulholland were presented with their certificates at a recent celebration and networking evening at RPS Scotland's building on Melville Street, Edinburgh, while the fellowship of the fourth pharmacist, Findlay Hickey, will be celebrated in 2023. The evening also saw RPS Scotland director Clare Morrison and General Pharmaceutical Council Scotland director Laura Fulton welcome a group of newly qualified pharmacists to the profession. Commenting on the evening's celebration, Morrison said: "It was an absolute pleasure to welcome pharmacists to our building in Edinburgh, the home of pharmacy in Scotland. The mood was so vibrant as people came together to celebrate and to network.

NHS England has commissioned the Royal Pharmaceutical Society (RPS) to develop guidance that helps community and hospital pharmacy teams across Britain to reduce the impact of pharmacy services, pharmaceutical care and medicines on the environment. The RPS said the Greener Pharmacy Guidance will enable pharmacies to self-assess their impact against the standards, benchmark and improve through evidence-based activities and actions. "I'm delighted our strong commitment to helping pharmacy reduce its environmental impact can now be taken to the next level through developing guidance and accreditation for pharmacy teams," RPS president Professor Claire Anderson said. "Medicines account for 25 per cent of carbon emissions within the NHS and this initiative underscores our commitment to promoting sustainable healthcare and supporting the NHS's goal of achieving 'net zero' emissions by 2040." Peter Morgan, medicines assistant director at NHS England, commented: "Pharmacy staff are involved in the purchasing and dispensing of almost every medicine used in the NHS and the new Greener Pharmacy Guidance and Self-accreditation scheme will provide support for pharmacy professionals by outlining clear actions to deliver more environmentally sustainable pharmacy practices." The RPS said the guidance and digital self-assessment toolkit will integrate with carbon calculator tools to help pharmacy teams to measure their carbon footprint, action plan to reduce use of carbon and improve sustainability.

Community Pharmacy England (CPE) to host a Parliamentary drop-in event in July to brief MPs and Peers about the ongoing medicines supply chain issues that are negatively affecting pharmacies and their patients across the country. CPE's Pressures Survey earlier this year highlighted the extent of both the operational and financial impacts of medicines supply issues on pharmacy businesses, therefore it has continued to hear from both pharmacy owners and others about the problems. The event aims to ensure that MPs understand the problems and their impact on pharmacies. Peter Dowd MP is hosting the event, joined by representatives from Community Pharmacy England, the Nuffield Trust, patient groups and more. The event will also be another opportunity to talk to MPs from across the political spectrum about the very serious situation that community pharmacies still find themselves in and the need for further investment in the sector. Janet Morrison OBE, Chief executive of Community Pharmacy England said: "The results of our Pressures Survey earlier this year showed just how much supply issues are continuing to negatively impact pharmacy businesses and all those who work in them. The survey found that almost all pharmacy owners (97%) are facing significant increases in wholesaler and medicine supply issues, with 71% saying this was leading to delays in prescriptions being issued.

The UK's National Health Service (NHS) has partnered with P-Wave, a urinal products brand, to put cancer warnings for men on urinal mats in public places across England, as part of its new earlier diagnosis drive. Urinal mats in pubs, restaurants, shops, hotels and sports stadiums will begin to carry the message "Blood in your pee? Contact your GP practice", and men's toilets in workplaces will also be targeted, the NHS said. Health chiefs believe that this unique initiative will help men to spot the signs of cancer such as blood in pee, and catch the disease early. "Having blood in your pee - even just once - shouldn't be ignored because it can be a sign of cancer, so it needs to be checked out by your GP team," said Professor Peter Johnson, NHS England National Clinical Director for Cancer.

British scientists said on Thursday (December 30) they would be studying whether higher doses of a cheap and widely used steroid called dexamethasone could work better for patients with severe Covid-19 compared to the standard low doses. Last year, the same scientists conducting the large trial, dubbed RECOVERY, showed that dexamethasone was able to save the lives of Covid-19 patients in what was called a "major breakthrough" in the coronavirus pandemic. They had found that a 6 mg daily dose of dexamethasone, which is used to reduce inflammation in diseases such as arthritis, cut death rates by around a third among the most severely ill Covid-19 patients in hospitals. "Given how quickly the Omicron variant is spreading, we can expect to see patients admitted to hospital with severe Covid-19 for a while to come," said Peter Horby, an Oxford University professor co-leading the trial.

Pfizer's oral Covid-19 therapy will be evaluated as a potential treatment for patients hospitalised with the illness in a major British trial, scientists said on Monday, as cases rise in some parts of the world. The world's largest randomised study of potential medicines for Covid-19, dubbed the RECOVERY trial, will assess Paxlovid across hospitals in Britain, which has already approved the drug for early-stage treatment. "Paxlovid is a promising oral antiviral drug but we don't know if it can improve survival of patients with severe Covid-19," said Peter Horby, a professor at the University of Oxford and joint chief investigator of the RECOVERY trial. The scientists said they aim to mainly find whether Pfizer's Paxlovid reduces the risk of death among patients admitted to hospitals with Covid-19.

The 'SaveOurPharmacies' roundtable held on Tuesday (21 March) to discuss severe challenges faced by the community pharmacies in England witnessed the support of 15 MPs. Janet Morrison, Chief Executive, Pharmaceutical Services Negotiating Committee (PSNC); Andrew Lane, independent pharmacy owner and Chairman, National Pharmacy Association (NPA) and Ian Strachan, independent pharmacy owner and Board Member, Association of Independent Multiple Pharmacies (AIM) attended the summit, which was chaired by Stephen Hammond MP, to brief MPs on the severe challenges facing the sector. MPs in attendance were Stephen Hammond, Sally-Ann Hart, Peter Aldous, Anna Firth, Taiwo Owatemi, Bob Seely, Derek Thomas, David Rutley, Lilian Greenwood, Tulip Siddiq, Hillary Benn, Sarah Olney, Christian Wakeford, Daisy Cooper (researcher) and Victoria Atkins (researcher) The title of the event 'Community pharmacy's role in the Primary Care Recovery Plan' which is expected imminently, is set to include a variety of measures aimed at helping primary care to recover from the impact of the pandemic. PSNC has been pressing for the plan to include a fully-funded national Pharmacy First service as this is the best chance for getting significant additional funds into community pharmacies.

Independent pharmacy chain, Peak Pharmacy, has sold two of its smaller branches - one in Little Eaton, Derbyshire, and the other in Burton-on-Trent, Staffordshire. Founded in 1981 by Peter and Jane Cattee, Peak Pharmacy has over 150 pharmacies across the UK. The pair of Midlands pharmacies dispense an average of circa 2,800 items per month, according to specialist business property adviser, Christie & Co, which announced the sale. The pharmacy in Burton-on-Trent has been acquired by a local first-time buyer, Mohammed Wasim Gul, while the pharmacy in Little Eaton has been purchased by Amul Telrandhe, who is also the owner of Derwent Pharmacy in Derby.

The Royal Pharmaceutical Society (RPS) recently announced a valuable addition to their e-library collection: the Maudsley Deprescribing Guidelines, authored by renowned experts Mark Horowitz and David Taylor. Designed to assist pharmacists and clinicians in recognising and appropriately treating withdrawal effects of medications, the guidelines have garnered praise from industry figures like Peter Pratt, National Speciality Advisor for Mental Health Pharmacy and RPS Fellow. This initiative responds to the increasing demand for guidance on safely reducing or discontinuing psychiatric medications, providing comprehensive support for clinicians and patients alike. Drawing on insights from contributors to The Lancet Psychiatry, the handbook offers step-by-step instructions for tapering antidepressants, benzodiazepines, gabapentinoids, and z-drugs, along with troubleshooting strategies.

Laganside Crown Court, on Friday, sentenced Gerard Cullinan, a 48-year-old pharmacist and Director of Castlereagh Pharmacy Ltd in East Belfast, for unlawfully supplying controlled prescription medicines, including co-codamol and fentanyl, and for failing to maintain controlled drugs registers. Cullinan was sentenced to 11 months imprisonment, suspended for three years, and his pharmacy was fined £8,000. The sentencing follows an investigation by the Department of Health's Medicines Regulatory Group (MRG), which uncovered that Cullinan's pharmacy on Castlereagh Road had illegally supplied over 300,000 co-codamol tablets between January 2017 and June 2020. Additionally, the MRG investigation identified significant breaches in record-keeping for Class A controlled drugs such as fentanyl, tapentadol, methylphenidate, morphine, and oxycodone. "It is a serious criminal offence to sell or supply prescription only medicines without a prescription," said Peter Moore, Senior Medicines Enforcement Officer at the MRG, who led the investigation.